alternative-therapies.com PubMed The interstitial cystitis pilot lacks a randomized control arm, is underpowered for robust efficacy conclusions and primarily signals feasibility and short term tolerability
In further embodiments, the auris formulation or composition contains a viscosity enhancing agent or viscosity modulating agent sufficient to provide a viscosity of between about 10 and 1,000,000 centipoise, between about 100 and 1,000,000 centipoise, between about 500 and 1,000,000 centipoise, between about 750 and 1,000,000 centipoise
The price is unbeatable for the results I'm seeing lately
The current anti-lipid medicines dont affect its levels much either the best drug we have now is the PCSK9 inhibitor, Evolocumab, which only reduces the levels of Lp(a) by about 20%